Brief: CStone Pharmaceuticals Says Blueprint Medicines Receives FDA Approval Of AYVAKIT
05/06/2023 07:09
June 5 (Reuters) - CStone Pharmaceuticals 2616.HK :
* BLUEPRINT MEDICINES ANNOUNCES FDA APPROVAL OF
AYVAKIT(AVAPRITINIB) FOR ADULTS WITH INDOLENT SYSTEMIC
MASTOCYTOSIS
Source text for Eikon: ID:nHKS3Xd85Q
Further company coverage: 2616.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026